Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02582879 · ClinicalTrials.gov registry record
informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia
A clinical trial of Chronic Lymphocytic Leukemia (CLL), sponsored by Pharmacyclics.
- Completed
- Registry status
- 1,504
- Enrollment target
- 20
- Study locations
NCT02582879: Completed study of Chronic Lymphocytic Leukemia (CLL), sponsored by Pharmacyclics.
NCT02582879 is a study of Chronic Lymphocytic Leukemia (CLL) that has completed, run by Pharmacyclics. The registered enrollment target is 1,504 participants, above the 140-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (974% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02582879, a study of Chronic Lymphocytic Leukemia (CLL), has completed, sponsored by Pharmacyclics.
- COMPLETED
- Registry status
- 1,504 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is designed as a multicenter, prospective, observational registry of CLL/SLL patients who are initiating approved oral kinase inhibitors, BCL-2 inhibitors or other approved anti-CLL therapies/regimens. The study will characterize treatment patterns and their association with patient characteristics, healthcare resource utilization, and clinical outcomes, as well as patient-reported outcome (PRO) measures.
Primary Outcome
\- Summarize baseline characteristics of study participants
Conditions Studied
Study Locations (20)
California
- John Muir Health - Concord
- North County Oncology Medical Clinic - Oceanside
- Sansum Clinic - Santa Barbara
- St Joseph Heritage Healthcare - Santa Rosa
- Sansum Clinic - Solvang
- Gregory Smith, MD (Private Practice) - St. Helena
- Solano Hematology Oncology - Vallejo
Arizona
- Arizona Oncology Associates, PC - HAL - Glendale
- Arizona Oncology Associates, PC - HAL - Phoenix
- Arizona Oncology Associates, PC - HAL - Phoenix
- Arizona Oncology Associates, PC - HAL-Scottsdale - Tempe
Arkansas
- Mercy Research - Fort Smith
- Genesis Cancer Center - Hot Springs
- Clopton Clinic of Jonesboro, Inc. - Jonesboro
- CARTI - Central Arkansas Radiation Therapy Institute - Little Rock
Colorado
- Rocky Mountain Cancer Centers, LLP- Aurora - Aurora
- Rocky Mountain Cancer Centers, LLP- Boulder - Boulder
- Rocky Mountain Cancer Centers - Colorado Springs
Alabama
- Clearview Cancer Institute - Huntsville
- Northwest Alabama Cancer Center, PC - Muscle Shoals
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,504 participants |
| Start Date | 2015-09 |
| Est. Completion | 2021-07-21 |
What the finished NCT02582879 record still lists
NCT02582879 is an observational study that tracks outcomes without assigning an intervention. Its 1,504 participants enrollment target places it among the larger protocols in the corpus, above the 140-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (974% higher).
The record links to 1 condition, with Chronic Lymphocytic Leukemia (CLL) appearing as the primary indexed condition, and to 0 interventions.
NCT02582879 names 20 study sites across 5 states, led by California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT02582879 about?
NCT02582879 is a clinical study titled "informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia". The study is designed as a multicenter, prospective, observational registry of CLL/SLL patients who are initiating approved oral kinase inhibitors, BCL-2 inhibitors or other approved anti-CLL therapies/regimens. The study will characterize treatment patterns and their association with patient charac...
What is the current status of trial NCT02582879?
This trial is currently completed. The enrollment target is 1,504 participants. The study started on 2015-09. Estimated completion is 2021-07-21.
What conditions does trial NCT02582879 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia (CLL).
Who is sponsoring clinical trial NCT02582879?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02582879 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia (CLL)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02582879's enrollment target sits among peer trials
1,504 1st of 29 higher than 29 of 29 other Chronic Lymphocytic Leukemia (CLL) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Lymphocytic Leukemia (CLL) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
RECRUITING · Phase 2
-
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
-
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
RECRUITING · Phase 2
-
Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- NCT02071134 · 1,500 participants
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia